{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,10]],"date-time":"2026-03-10T17:02:15Z","timestamp":1773162135669,"version":"3.50.1"},"reference-count":28,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2024,4,1]],"date-time":"2024-04-01T00:00:00Z","timestamp":1711929600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,4,1]],"date-time":"2024-04-01T00:00:00Z","timestamp":1711929600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2024,4,1]],"date-time":"2024-04-01T00:00:00Z","timestamp":1711929600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2024,4,1]],"date-time":"2024-04-01T00:00:00Z","timestamp":1711929600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2024,4,1]],"date-time":"2024-04-01T00:00:00Z","timestamp":1711929600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2024,4,1]],"date-time":"2024-04-01T00:00:00Z","timestamp":1711929600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100005150","name":"Chinese Academy of Medical Sciences & Peking Union Medical College","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100005150","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Medicinal Chemistry"],"published-print":{"date-parts":[[2024,4]]},"DOI":"10.1016\/j.ejmech.2024.116327","type":"journal-article","created":{"date-parts":[[2024,3,15]],"date-time":"2024-03-15T08:28:54Z","timestamp":1710491334000},"page":"116327","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":3,"special_numbering":"C","title":["Proline-derived quinoline formamide compounds as human urate transporter 1 inhibitors with potent uric acid-lowering activities"],"prefix":"10.1016","volume":"269","author":[{"given":"Shengnan","family":"Li","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hui","family":"Liao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lijun","family":"Luo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bingxu","family":"Meng","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fengxin","family":"Zheng","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Li","family":"Sheng","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hongyi","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yi","family":"Huan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lei","family":"Lei","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jiayu","family":"Zhai","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kunlu","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jinhong","family":"Tian","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ting","family":"Wu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0924-7950","authenticated-orcid":false,"given":"Gang","family":"Li","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jianxin","family":"Pang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Haihong","family":"Huang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.ejmech.2024.116327_bib1","doi-asserted-by":"crossref","first-page":"679","DOI":"10.1016\/j.amjmed.2011.09.033","article-title":"Comorbidities of gout and hyperuricemia in the US general population: NHANES 2007-2008","volume":"125","author":"Zhu","year":"2012","journal-title":"Am. J. Med."},{"key":"10.1016\/j.ejmech.2024.116327_bib2","doi-asserted-by":"crossref","first-page":"1013","DOI":"10.1517\/13543784.2015.1051617","article-title":"Investigational drugs for hyperuricemia","volume":"24","author":"Shahid","year":"2015","journal-title":"Expet Opin. Invest. Drugs"},{"key":"10.1016\/j.ejmech.2024.116327_bib3","first-page":"178","article-title":"The latest research progress of uric acid lowering drugs","volume":"20","author":"Hou","year":"2019","journal-title":"CJITWN"},{"key":"10.1016\/j.ejmech.2024.116327_bib4","doi-asserted-by":"crossref","first-page":"475","DOI":"10.1097\/00041552-200209000-00001","article-title":"Part 1. Uric acid and losartan","volume":"11","author":"Sica","year":"2002","journal-title":"Curr. Opin. Nephrol. Hypertens."},{"key":"10.1016\/j.ejmech.2024.116327_bib5","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1007\/s10157-005-0368-5","article-title":"Roles of organic anion transporters (OATs) and a urate transporter (URAT1) in the pathophysiology of human disease","volume":"9","author":"Enomoto","year":"2005","journal-title":"Clin. Exp. Nephrol."},{"key":"10.1016\/j.ejmech.2024.116327_bib6","doi-asserted-by":"crossref","first-page":"200","DOI":"10.1016\/j.pharmthera.2010.02.007","article-title":"Therapeutic implications of renal anionic drug transporters","volume":"126","author":"Masereeuw","year":"2010","journal-title":"Pharmacol. Ther."},{"key":"10.1016\/j.ejmech.2024.116327_bib7","doi-asserted-by":"crossref","first-page":"15501","DOI":"10.1073\/pnas.0904411106","article-title":"Glut9 is a major regulator of urate homeostasis and its genetic inactivation induces hyperuricosuria and urate nephropathy","volume":"106","author":"Preitner","year":"2009","journal-title":"Proc. Natl. Acad. Sci. U.S.A."},{"key":"10.1016\/j.ejmech.2024.116327_bib8","first-page":"2261","article-title":"Research progress on uric acid transport related proteins SLC2A9\/GLUT9","volume":"34","author":"Liu","year":"2013","journal-title":"Guangdong Medicine"},{"key":"10.1016\/j.ejmech.2024.116327_bib9","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2021.114092","article-title":"Discovery of novel Verinurad analogs as dual inhibitors of URAT1 and GLUT9 with improved druggability for the treatment of hyperuricemia","volume":"229","author":"Zhao","year":"2022","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.ejmech.2024.116327_bib10","doi-asserted-by":"crossref","first-page":"S2","DOI":"10.1016\/j.semarthrit.2020.04.007","article-title":"The biology of urate","volume":"50","author":"Keenan","year":"2020","journal-title":"Semin. Arthritis Rheum."},{"key":"10.1016\/j.ejmech.2024.116327_bib11","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1016\/j.pharmthera.2012.07.010","article-title":"Drug transport by organic anion transporters (OATs)","volume":"136","author":"Burckhardt","year":"2012","journal-title":"Pharmacol. Ther."},{"key":"10.1016\/j.ejmech.2024.116327_bib12","doi-asserted-by":"crossref","first-page":"1201","DOI":"10.1080\/14656566.2017.1351945","article-title":"Current and future therapies for gout","volume":"18","author":"Pascart","year":"2017","journal-title":"Expet Opin. Pharmacother."},{"key":"10.1016\/j.ejmech.2024.116327_bib13","doi-asserted-by":"crossref","first-page":"1115","DOI":"10.1080\/14656566.2017.1349099","article-title":"Updates on the treatment of gout, including a review of updated treatment guidelines and use of small molecule therapies for difficult-to-treat gout and gout flares","volume":"18","author":"Soskind","year":"2017","journal-title":"Expet Opin. Pharmacother."},{"key":"10.1016\/j.ejmech.2024.116327_bib14","doi-asserted-by":"crossref","first-page":"871","DOI":"10.1080\/13543776.2019.1676727","article-title":"Novel Urate Transporter 1 (URAT1) inhibitors: a review of recent patent literature (2016-2019)","volume":"29","author":"Dong","year":"2019","journal-title":"Expert Opin. Ther. Pat."},{"key":"10.1016\/j.ejmech.2024.116327_bib15","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejphar.2021.174291","article-title":"A brief review of Urate Transporter 1 (URAT1) inhibitors for the treatment of hyperuricemia and gout: current therapeutic options and potential applications","volume":"907","author":"Song","year":"2021","journal-title":"Eur. J. Pharmacol."},{"key":"10.1016\/j.ejmech.2024.116327_bib16","doi-asserted-by":"crossref","first-page":"1175","DOI":"10.1080\/13543776.2022.2165911","article-title":"Novel Urate Transporter 1 (URAT1) inhibitors: a review of recent patent literature (2020-Present)","volume":"32","author":"Shi","year":"2022","journal-title":"Expert Opin. Ther. Pat."},{"key":"10.1016\/j.ejmech.2024.116327_bib17","doi-asserted-by":"crossref","first-page":"925","DOI":"10.1002\/hep.20634","article-title":"Mechanisms of Benzarone and Benzbromarone induced hepatic toxicity","volume":"41","author":"Kaufmann","year":"2005","journal-title":"Hepatology"},{"key":"10.1016\/j.ejmech.2024.116327_bib18","doi-asserted-by":"crossref","first-page":"2017","DOI":"10.1021\/acsmedchemlett.0c00176","article-title":"Discovery of Dotinurad (FYU-981), a new phenol derivative with highly potent uric acid lowering activity","volume":"11","author":"Uda","year":"2020","journal-title":"ACS Med. Chem. Lett."},{"key":"10.1016\/j.ejmech.2024.116327_bib19","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1016\/j.bmcl.2015.12.040","article-title":"Discovery of potent and orally bioavailable inhibitors of Human Uric Acid Transporter 1 (hURAT1) and binding mode prediction using homology model","volume":"26","author":"Peng","year":"2016","journal-title":"Bioorg. Med. Chem. Lett."},{"key":"10.1016\/j.ejmech.2024.116327_bib20","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2023.115532","article-title":"Identification of 5-[5-cyano-1-(pyridin-2-ylmethyl)-1H-indole-3-carboxamido] thiazole-4-carboxylic acid as a promising dual inhibitor of urate transporter 1 and xanthine oxidase","volume":"257","author":"Lin","year":"2023","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.ejmech.2024.116327_bib21","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1038\/s41401-021-00640-5","article-title":"CDER167, a dual inhibitor of URAT1 and GLUT9, is a novel and potent uricosuric candidate for the treatment of hyperuricemia","volume":"43","author":"Zhao","year":"2022","journal-title":"Acta Pharmacol. Sin."},{"key":"10.1016\/j.ejmech.2024.116327_bib22","doi-asserted-by":"crossref","first-page":"2701","DOI":"10.1021\/jm1015022","article-title":"Developing potent human uric acid transporter 1 (hURAT1) inhibitors","volume":"54","author":"Wempe","year":"2011","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejmech.2024.116327_bib23","doi-asserted-by":"crossref","first-page":"180","DOI":"10.1152\/physiolgenomics.00207.2007","article-title":"Multiple Organic Anion Transporters contribute to net renal excretion of uric acid","volume":"33","author":"Eraly","year":"2008","journal-title":"Physiol. Genom."},{"key":"10.1016\/j.ejmech.2024.116327_bib24","doi-asserted-by":"crossref","first-page":"3755","DOI":"10.1038\/srep03755","article-title":"ABCG2 dysfunction causes hyperuricemia due to both renal urate underexcretion and renal urate overload","volume":"4","author":"Matsuo","year":"2014","journal-title":"Sci. Rep."},{"key":"10.1016\/j.ejmech.2024.116327_bib25","doi-asserted-by":"crossref","first-page":"518","DOI":"10.3389\/fphar.2016.00518","article-title":"Identification of Febuxostat as a new strong ABCG2 inhibitor: potential applications and risks in clinical situations","volume":"7","author":"Miyata","year":"2016","journal-title":"Front. Pharmacol."},{"key":"10.1016\/j.ejmech.2024.116327_bib26","first-page":"1679","article-title":"Research progress on natural products with uric acid lowering or anti gout activity","volume":"57","author":"Zhang","year":"2022","journal-title":"Acta Pharm. Sin."},{"key":"10.1016\/j.ejmech.2024.116327_bib27","first-page":"1696","article-title":"Research progress on the pathogenesis of gout","volume":"35","author":"Dong","year":"2015","journal-title":"Basic & Clin. Med."},{"key":"10.1016\/j.ejmech.2024.116327_bib28","doi-asserted-by":"crossref","first-page":"4218","DOI":"10.1021\/acs.jmedchem.1c02057","article-title":"Discovery of novel bicyclic imidazolopyridine-containing Human Urate Transporter 1 inhibitors as hypouricemic drug candidates with improved efficacy and favorable druggability","volume":"65","author":"Zhao","year":"2022","journal-title":"J. Med. Chem."}],"container-title":["European Journal of Medicinal Chemistry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0223523424002071?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0223523424002071?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,4,6]],"date-time":"2024-04-06T05:05:57Z","timestamp":1712379957000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0223523424002071"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,4]]},"references-count":28,"alternative-id":["S0223523424002071"],"URL":"https:\/\/doi.org\/10.1016\/j.ejmech.2024.116327","relation":{},"ISSN":["0223-5234"],"issn-type":[{"value":"0223-5234","type":"print"}],"subject":[],"published":{"date-parts":[[2024,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Proline-derived quinoline formamide compounds as human urate transporter 1 inhibitors with potent uric acid-lowering activities","name":"articletitle","label":"Article Title"},{"value":"European Journal of Medicinal Chemistry","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ejmech.2024.116327","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 Elsevier Masson SAS. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"116327"}}